|Dr. Phillip Frost||Chairman & CEO||971k||N/A||1936|
|Dr. Jane H. Hsiao M.B.A., Ph.D., MBA||Vice Chairman & Chief Technical Officer||911k||N/A||1947|
|Mr. Adam E. Logal||Sr. VP, CFO, Chief Accounting Officer & Treasurer||611k||62.25k||1978|
|Mr. Steven D. Rubin||Exec. VP of Admin. & Director||821k||N/A||1960|
|Ms. Kate Inman||Gen. Counsel & Sec.||N/A||N/A||1973|
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services. The Bio-Reference Laboratories also provides core genetic testing and leverage products, such as the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. The company's Pharmaceutical segment offers Rayaldee, a treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, a selective androgen receptor modulator for benign prostatic hyperplasia, and other urologic and metabolic conditions; and OPK88003, a once or twice weekly oxyntomodulin that is in Phase II trials for type 2 diabetes and obesity. It is also developing hGH-CTP, a once-weekly human growth hormone injection in Phase III clinical trial in partnership with Pfizer, Inc.; VARUBI for chemotherapy-induced nausea and vomiting; and Factor VIIa drug for hemophilia. In addition, this segment develops and produces specialty active pharmaceutical ingredients; and discovers drugs for the treatment of cancer, heart disease, metabolic disorders, and a range of genetic anomalies. Further, it develops, manufactures, markets, and sells pharmaceutical, nutraceutical, and veterinary products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro- intestinal products, hormones, and others. Additionally, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.
OPKO Health, Inc.’s ISS Governance QualityScore as of June 25, 2019 is 7. The pillar scores are Audit: 5; Board: 9; Shareholder Rights: 3; Compensation: 6.